| Chronic Obstructive Airway Disease
Bevespi Aerosphere vs Breyna
Side-by-side clinical, coverage, and cost comparison for chronic obstructive airway disease.Deep comparison between: Bevespi Aerosphere vs Breyna with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsBreyna has a higher rate of injection site reactions vs Bevespi Aerosphere based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Breyna but not Bevespi Aerosphere, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Bevespi Aerosphere
Breyna
At A Glance
Oral inhalation
Twice daily
LAMA/LABA combination
Oral inhalation
Twice daily
ICS/LABA combination
Indications
- Chronic Obstructive Airway Disease
- Asthma
- Chronic Obstructive Airway Disease
- Bronchitis, Chronic
- Pulmonary Emphysema
Dosing
Chronic Obstructive Airway Disease 2 inhalations (glycopyrrolate 18 mcg and formoterol fumarate 9.6 mcg) twice daily in the morning and evening by oral inhalation; do not exceed two inhalations twice daily.
Asthma (12 years and older) 2 inhalations of 80 mcg/4.5 mcg or 160 mcg/4.5 mcg twice daily by oral inhalation; starting dose based on asthma severity.
Asthma (6 to <12 years) 2 inhalations of 80 mcg/4.5 mcg twice daily by oral inhalation.
Chronic Obstructive Airway Disease, Bronchitis, Chronic, Pulmonary Emphysema 2 inhalations of 160 mcg/4.5 mcg twice daily by oral inhalation.
Contraindications
- Use of a long-acting beta2-adrenergic agonist (LABA), including formoterol fumarate, without an inhaled corticosteroid in patients with asthma
- Hypersensitivity to glycopyrrolate, formoterol fumarate, or any component of the product
- Primary treatment of status asthmaticus or other acute episodes of asthma or COPD where intensive measures are required
- Hypersensitivity to any ingredient in BREYNA
Adverse Reactions
Most common (>=2%) Cough, urinary tract infection
Serious Paradoxical bronchospasm, hypersensitivity reactions including anaphylaxis, cardiovascular effects, worsening of narrow-angle glaucoma, worsening of urinary retention
Postmarketing Hypersensitivity, urinary retention
Most common (>=3%) Nasopharyngitis, headache, upper respiratory tract infection, pharyngolaryngeal pain, sinusitis, oral candidiasis, bronchitis, influenza
Serious Serious asthma-related events (hospitalizations, intubations, death), cardiovascular and CNS effects, Candida albicans infection, pneumonia or lower respiratory tract infections in COPD, immunosuppression, hypercorticism, adrenal suppression
Postmarketing Angina pectoris, tachycardia, atrial fibrillation, cataract, glaucoma, oropharyngeal candidiasis, anaphylactic reaction, hyperglycemia, hypokalemia, tremor, dysphonia, hypotension, hypertension
Pharmacology
BEVESPI AEROSPHERE combines glycopyrrolate, a long-acting anticholinergic (LAMA) that inhibits M3 muscarinic receptors in airway smooth muscle to produce bronchodilation, with formoterol fumarate, a long-acting selective beta2-adrenoceptor agonist (LABA) that stimulates adenyl cyclase to increase cyclic AMP, relaxing bronchial smooth muscle and inhibiting mediator release from mast cells.
Budesonide is an inhaled corticosteroid that suppresses inflammation by inhibiting multiple cell types and mediators involved in allergic and non-allergic inflammation; formoterol is a long-acting selective beta2-adrenergic agonist that relaxes bronchial smooth muscle by stimulating adenyl cyclase and increasing intracellular cyclic AMP.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Bevespi Aerosphere
- Covered on 5 commercial plans
- PA (4/12) · Step Therapy (5/12) · Qty limit (9/12)
Breyna
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Bevespi Aerosphere
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (6/8)
Breyna
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Bevespi Aerosphere
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Breyna
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (1/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Bevespi Aerosphere.
No savings programs available for Breyna.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Bevespi AerosphereView full Bevespi Aerosphere profile
BreynaView full Breyna profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.